Elpen Participates Dynamically in Be Pharma 2025

Elpen continues to participate in major international exhibitions, focusing on enhancing its global presence. As part of this effort, it participated in the international Be Pharma exhibition, the largest B2B event in Latin America. The event took place in Mexico from March 31 to April 1, 2025. During the exhibition, Elpen’s representatives held meetings with local companies to discuss the company’s activities and the requirements for penetrating the Mexican pharmaceutical market. Export orientation is a key element in Elpen’s philosophy. Its export activities began in the 1990s, and today its products are exported to over 90 countries worldwide. In the last two years, the company has achieved a 200% increase in sales from markets outside Greece. Since 2012, Elpen has operated ELPEN Pharma GmbH, a subsidiary in Germany, where its drugs have long been recognized for their quality. In 2024, Elpen expanded into one of the fastest-growing healthcare markets by establishing a subsidiary in Dubai, UAE. This year’s Be Pharma attracted 166 companies with representatives from Central America to Chile. Notably, besides the large pharmaceutical companies active in Mexico, the event drew increasing interest from international firms.